Voyager Therapeutics, Inc. (VYGR) Form 8-K — Aug 6, 2026
Voyager Therapeutics reported second quarter 2026 results on August 6, 2026, with collaboration revenue of $3.2 million, down from $5.2 million a year earlier as the Neurocrine collaboration moved beyond its research phase. Net loss narrowed to $24.5 million from $33.4 million, helped by R&D spending that fell to $22.0 million from $31.3 million following program prioritization and 2025 restructuring. The company ended the quarter with $148.8 million in cash, cash equivalents and marketable securities, down from $201.7 million at year-end 2025, and said the balance plus collaboration reimbursements and interest income is sufficient to fund operations into 2028.
Key figures
- Revenue
- $3.2 million Q2 2026 collaboration revenue
- Guidance
- Cash, equivalents and marketable securities plus anticipated collaboration reimbursements and interest income expected to fund operations into 2028; VY7523 tau PET data and VY1706 dosing both expected Q4 2026.
- Net Income
- -$24.5 million Q2 2026 net loss (vs. -$33.4 million Q2 2025)
- Revenue Yoy
- -39% (vs. $5.2 million in Q2 2025)
- Total Assets
- $197.8 million
- Cash Position
- $148.8 million (cash, cash equivalents and marketable securities as of June 30, 2026)
- Cash dec 31 2025
- $201.7 million
- Ga expense q2 2026
- $7.5 million (vs. $10.5 million Q2 2025)
- Rnd expense q2 2026
- $22.0 million (vs. $31.3 million Q2 2025)
- Tau reduction nhp tox
- up to 75% sustained tau protein reduction in key AD brain regions after single IV dose (6-month GLP NHP data)
- Net rnd expense q2 2026
- $19.0 million (non-GAAP)
- Six month net loss 2026
- $52.4 million (vs. $64.4 million prior year)
- Weighted avg shares q2 2026
- 60547863
- Net collaboration revenue q2 2026
- $0.151 million (non-GAAP, ex-reimbursements)
Price after filing
Close on the filing date to close N calendar days later (from $3.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.